Barclays Starts Insulet Corporation (PODD) at Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro boost AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
Tweet
Share
E-mailGet Alerts PODD Hot Sheet
Price: $142.26 -0.27%
Rating Summary:
22 Buy, 18 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 17 | New: 14
Rating Summary:
22 Buy, 18 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 17 | New: 14
Join SI Premium – FREE
Barclays analyst Matt Miksic initiates coverage on Insulet Corporation (NASDAQ: PODD) with a Equalweight rating and a price target of $150.00.
For an analyst ratings summary and ratings history on Insulet Corporation click here. For more ratings news on Insulet Corporation click here.
Shares of Insulet Corporation closed at $135.62 yesterday.
You May Also Be Interested In
- Guggenheim Starts Kazia Therapeutics (KZIA) at Buy
- Raymond James Starts Xilio Therapeutics Inc (XLO) at Outperform
- WBB Securities Starts CytoSorbents (CTSO) at Speculative Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
